Interested in Theranostics ? Diagnostics And Drugs Should Be Co-Developed Early | GenomeWeb

BOSTON — Proteomics researchers in academia and industry wishing to play a role in the emerging “theranostics” market should consider partnering with drug or diagnostic companies early in the pre-clinical stages of product development, scientists said during a session at the Biomarker Pipeline conference, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.